Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to $723.2 billion.

  • Addex Therapeutics' Free Cash Flow fell 7019.73% to $723.2 billion in Q2 2025 from the same period last year, while for Sep 2025 it was $6162.9 billion, marking a year-over-year increase of 20225.14%. This contributed to the annual value of -$6.1 million for FY2024, which is 3140.48% up from last year.
  • Latest data reveals that Addex Therapeutics reported Free Cash Flow of $723.2 billion as of Q2 2025, which was down 7019.73% from -$665.9 billion recorded in Q1 2025.
  • Over the past 5 years, Addex Therapeutics' Free Cash Flow peaked at $8301.5 billion during Q4 2023, and registered a low of -$6175.0 billion during Q3 2024.
  • For the 4-year period, Addex Therapeutics' Free Cash Flow averaged around -$2.3 billion, with its median value being -$4.2 million (2022).
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 26025235328.27% in 2023, then tumbled by 9865764921.29% in 2024.
  • Over the past 4 years, Addex Therapeutics' Free Cash Flow (Quarter) stood at -$3.2 million in 2022, then surged by 260252353.28% to $8301.5 billion in 2023, then fell by 26.45% to $6105.7 billion in 2024, then tumbled by 88.16% to $723.2 billion in 2025.
  • Its last three reported values are $723.2 billion in Q2 2025, -$665.9 billion for Q1 2025, and $6105.7 billion during Q4 2024.